Table 1 Regimens, Duration, and Efficacy for Four Treatment Scenarios Modeled
From: Short-term budget affordability of hepatitis C treatments for state Medicaid programs
Baseline | Remove Sobriety Restrictions | Treat Early | Remove Access Restrictions | ||||||
|---|---|---|---|---|---|---|---|---|---|
North Carolina | F2+, Treat 6%, no PWIDs | F2+, Treat 6%, Treat PWIDs | F0+, Treat 8%, No PWIDs | F0+, Treat 8%, Treat PWIDs | |||||
Oregon | F3+, Treat 10%, no PWIDs | F3+, Treat 10%, Treat PWIDs | F0+, Treat 13%, No PWIDs | F0+, Treat 13%, Treat PWIDs | |||||
Wisconsin | F3+, Treat 18%, no PWIDs | F3+, Treat 18%, Treat PWIDs | F0+, Treat 24%, No PWIDs | F0+, Treat 24%, Treat PWIDs | |||||
Drugs used | sofosbuvir + velpatasvir for 12 weeks | ||||||||
SVR by disease stage | F0-F3 | F4, DC, HCC | F0-F3 | F4, DC, HCC | F0-F3 | F4, DC, HCC | F0-F3 | F4, DC, HCC | |
Genotype 1 | At Risk | 0.98 | 1.00 | Same as Baseline | |||||
PWID | 0.98 | 1.00 | Same as Baseline | ||||||
HIV+/MSM | 0.96 | 0.96 | Same as Baseline | ||||||
Genotype 2 | At Risk | 0.99 | 1.00 | Same as Baseline | |||||
PWID | 0.99 | 1.00 | Same as Baseline | ||||||
HIV+/MSM | 1.00 | 1.00 | Same as Baseline | ||||||
Genotype 3 | At Risk | 0.97 | 0.92 | Same as Baseline | |||||
PWID | 0.97 | 0.92 | Same as Baseline | ||||||
HIV+/MSM | 0.92 | 0.91 | Same as Baseline | ||||||